page contents

The Insider’s Guide to Alzheimer Drugs

Alzheimer’s Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2019 2025

(MENAFN – EIN) Wise.Guy.

1000mg CBD Lemon Flavor Presents ‘Global Alzheimer’s Drugs Market Research Report 2019’ New Document to its Studies Database alzheimer drugs

PUNE, INDIA, March 28, 2019 / / —

The global Alzheimer’s Drugs market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.This report focuses on Alzheimer Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Alzheimer’s Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:Ono PharmaceuticalJohnson & JohnsonDaiichi Sankyo Company LimitedH Lundbeck A/SEisai Co Ltd….

Request Free Sample Report @

Segment by RegionsNorth AmericaEuropeChinaJapan

Segment by TypeCholinergicMemantineCombined Drug

Segment by ApplicationHospital PharmacyRetail PharmacyOnline Sales

Complete Report Details @

Table Of Contents:

1 Alzheimer’s Drugs Market Overview1.1 Product Overview and Scope of Alzheimer’s Drugs1.2 Alzheimer’s Drugs Segment by Type1.2.1 Global Alzheimer’s Drugs Production Growth Rate Comparison by Type (2014-2025)1.2.2 Cholinergic1.2.3 Memantine1.2.4 Combined Drug1.3 Alzheimer’s Drugs Segment by Application1.3.1 Alzheimer’s Drugs Consumption Comparison by Application (2014-2025)1.3.2 Hospital Pharmacy1.3.3 Retail Pharmacy1.3.4 Online Sales1.4 Global Alzheimer’s Drugs Market by Region1.4.1 Global Alzheimer’s Drugs Market Size Region1.4.2 North America Status and Prospect (2014-2025)1.4.3 Europe Status and Prospect (2014-2025)1.4.4 China Status and Prospect (2014-2025)1.4.5 Japan Status and Prospect (2014-2025)1.5 Global Alzheimer’s Drugs Market Size1.5.1 Global Alzheimer’s Drugs Revenue (2014-2025)1.5.2 Global Alzheimer’s Drugs Production (2014-2025)

2 Global Alzheimer’s Drugs Market Competition by Manufacturers2.1 Global Alzheimer’s Drugs Production Market Share by Manufacturers (2014-2019)2.2 Global Alzheimer’s Drugs Revenue Share by Manufacturers (2014-2019)2.3 Global Alzheimer’s Drugs Average Price by Manufacturers (2014-2019)2.4 Manufacturers Alzheimer’s Drugs Production Sites, Area Served, Product Types2.5 Alzheimer’s Drugs Market Competitive Situation and Trends2.5.1 Alzheimer’s Drugs Market Concentration Rate2.5.2 Alzheimer’s Drugs Market Share of Top 3 and Top 5 Manufacturers2.5.3 Mergers & Acquisitions, Expansion

7 Company Profiles and Key Figures in Alzheimer’s Drugs Business7.1 Ono Pharmaceutical7.1.1 Ono Pharmaceutical Alzheimer’s Drugs Production Sites and Area Served7.1.2 Alzheimer’s Drugs Product Introduction, Application and Specification7.1.3 Ono Pharmaceutical Alzheimer’s Drugs Production, Revenue, Price and Gross Margin (2014-2019)7.1.4 Main Business and Markets Served7.2 Johnson & Johnson7.2.1 Johnson & Johnson Alzheimer’s Drugs Production Sites and Area Served7.2.2 Alzheimer’s Drugs Product Introduction, Application and Specification7.2.3 Johnson & Johnson Alzheimer’s Drugs Production, Revenue, Price and Gross Margin (2014-2019)7.2.4 Main Business and Markets Served7.3 Daiichi Sankyo Company Limited7.3.1 Daiichi Sankyo Company Limited Alzheimer’s Drugs Production Sites and Area Served7.3.2 Alzheimer’s Drugs Product Introduction, Application and Specification7.3.3 Daiichi Sankyo Company Limited Alzheimer’s Drugs Production, Revenue, Price and Gross Margin (2014-2019)7.3.4 Main Business and Markets Served7.4 H Lundbeck A/S7.4.1 H Lundbeck A/S Alzheimer’s Drugs Production Sites and Area Served7.4.2 Alzheimer’s Drugs Product Introduction, Application and Specification7.4.3 H Lundbeck A/S Alzheimer’s Drugs Production, Revenue, Price and Gross Margin (2014-2019)7.4.4 Main Business and Markets Served7.5 Eisai Co Ltd.7.5.1 Eisai Co Ltd. Alzheimer’s Drugs Production Sites and Area Served7.5.2 Alzheimer’s Drugs Product Introduction, Application and Specification7.5.3 Eisai Co Ltd. Alzheimer’s Drugs Production, Revenue, Price and Gross Margin (2014-2019)7.5.4 Main Business and Markets Served



Norah TrentWiseGuy Research Consultants Pvt. Ltd.646 845 9349 / +44 208 133 9349email us here[“facebook”, “twitter”, “google”, “linkedin”]{“facebook”=>””, “twitter”=>””, “google”=>””, “linkedin”=>””}


Alzheimer's Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2019 2025

EIN Presswire publishes and distributes press releases worldwide for small and mid-sized companies both public and private. Specializing in industry and business, topic categories range from agriculture and aviation to pharma and technology. The company was founded in 1995.


1 Surprising Reason Alzheimer’s Drugs Remain So Elusive

When Biogen (NASDAQ:BIIB) and Eisai announced their decision to pull the plug on a late-stage trial for aducanumab in treating Alzheimer’s disease, it was just the latest in a long string of failures for experimental treatments targeting the neurodegenerative disease. The failure looks like the last nail in the coffin for the amyloid hypothesis, which postulates that the accumulation of beta-amyloid proteins in brain cells is the root cause of the disease. But researchers might not have to travel all the way back to square one in the search for an effective Alzheimer’s treatment.

A lesser-known hypothesis about the pathology of Alzheimer’s disease hasn’t received much attention from investors or biopharmaceutical companies, but it may emerge as the next logical step on the path to developing successful therapies. It could even allow previously abandoned drugs to be brought back to life. To get up to speed on the investing opportunities and potential biopharma partnerships on the horizon, investors have to visit a field that might not be on their radar: sleep science.

A man sleeping

Image Source: Getty Images

Is sleep the missing piece of the Alzheimer’s puzzle?

The amyloid hypothesis is pretty straightforward: Over time, brain cells can lose their ability to efficiently clear beta-amyloid proteins, forming plaques that disrupt cellular communication (there’s a similar hypothesis incorporating tau proteins and other cellular wastes). The thinking goes that a drug aimed at restoring the ability to clear cellular wastes from brain cells could at least stop the progression of Alzheimer’s disease. But clinical results in the last decade cast doubt on this simplistic hypothesis, and its accompanying one-and-done drug approach.

Sleep scientists are beginning to understand why. In his recent book Why We Sleep, University of California, Berkeley professor of neuroscience and psychology Dr. Matthew Walker describes the strengthening link between sleep and dementia. Electrical patterns characterizing significant sleep disturbance, especially of non-rapid eye movement (NREM) sleep, “precedes the onset of Alzheimer’s disease by several years.” After diagnosis, the severity of sleep disturbance correlates with the severity of dementia. It makes sense: NREM sleep is when your brain is most efficient at clearing cellular wastes, including beta-amyloid and tau proteins — and also at consolidating memories.

The emerging link between Alzheimer’s and sleep disturbance provides a more complete picture of disease progression. For instance, beta-amyloid plaques only accumulate in certain regions of the brain (such as those associated with sleep), but not others (such as those associated with memory). This has always stumped scientists. Similarly, the link to sleep might explain why removing plaques from brain cells (the primary mechanism of many experimental Alzheimer’s drugs) without improving sleep quality generally fails to improve memory (the endpoints of many Alzheimer’s clinical studies). With more than 60% of individuals with dementia also having a co-occurring sleep disorder such as insomnia, it’s time to investigate the link more seriously.

Research is being conducted to cement the link between sleep disturbance, plaque formation, and dementia. Encouragingly, if the link holds up, then diagnosing at-risk individuals early on becomes relatively simple, just by using low-cost and non-invasive equipment that reads electrical signals from the brain. Equipment that works in reverse — sending electrical signals to the brain — is being studied for its potential to artificially improve sleep quality and memory. In other words, perhaps the future of Alzheimer’s treatments resides in devices, not drugs.

It might even make sense to develop combination therapies comprising electrical stimulation of the brain and plaque-clearing drugs to bolster the potential therapeutic effect. That could allow companies such as Biogen to resurrect drugs that failed previous clinical trials, with new trial designs and endpoints.

A woman getting an EEG.

Image source: Getty Images.

Which companies can diagnose sleep disorders?

Biopharmaceutical companies, as well as greater society, tend to neglect the importance of sleep to health. That means investors will need to get familiar with some new players in sleep analysis, called polysomnography, that could become important partners as the healthcare industry begins to recognize the value in studying sleep.

Koninklijke Philips N.V. (NYSE:PHG), commonly called Phillips in the U.S. might be the biggest catch for biopharmaceutical companies eager to develop a successful Alzheimer’s treatment that includes improving sleep quality. The company’s sleep and respiratory business segment was established through its 2007 acquisition of Respironics for $5 billion.

The medical equipment titan plans to move 1,250 employees into a new 200,000-square-foot office in a Pittsburgh innovation corridor, enjoying access to an educated workforce, as well as proximity to the University of Pittsburgh Medical Center, a biopharma clinical study hotspot. The growth potential could take on a new trajectory if more doctors and companies start exploring sleep as a factor in Alzheimer‘s disease, beyond the better-understood sleep disorders like sleep apnea, chronic obstructive pulmonary disease, and insomnia.

Phillips isn’t the only company with high hopes for its sleep and neurodiagnostics portfolio. Natus Medical (NASDAQ:BABY) provides sleep analysis hardware in its neuro business segment, which generated 53%, or $281 million, of the company’s total revenue in 2018. It’s in the process of shoring up operational deficiencies in 2019, but the neuro segment was its top growth driver last year. If more doctors and biopharmaceutical companies begin exploring the role of sleep in dementia, then the company’s portfolio and expertise could be in demand.

Puzzle in brain indicating Alzheimer's

Image Source: Getty Images

Alzheimer’s drugs remain elusive, but sleep science holds promise

A long string of failures in the clinic strongly suggests the beta-amyloid hypothesis is insufficient in fully explaining the causes and progression of Alzheimer’s disease. Sleep scientists think they’re on the path to offering a more complete picture, while simultaneously tying up some perplexing scientific loose ends, such as why plaques aren’t observed in brain regions responsible for memory formation, despite memory loss being a hallmark of neurodegenerative diseases falling under the dementia umbrella.

That prompts the question: Would biopharma companies have more success developing Alzheimer’s treatments if they focused on both removing plaques and improving sleep quality? Perhaps. The evidence is certainly beginning to lead scientists to prioritize sleep quality as a treatment, but whether drugs would provide a significant clinical benefit (and be worth the assumed high cost) in such a combination therapy remains unknown.

That said, investors shouldn’t rush to add Phillips and Natus Medical to their portfolios just yet. While these companies are leaders in the emerging sector of sleep analysis today, they may not move the needle for individual investors interested in supporting the development of an Alzheimer’s treatment. It may be best to simply wait and see if an established biopharma company forays into sleep science first. It’s starting to look like being first to understanding how sleep factors into the development of dementia will be the next competitive advantage sought by both emerging players and established biopharmas alike.


Wall Street Is Ditching Amyloid-based Alzheimer’s Drugs — It Shouldn’t, Scientists Say

After Biogen Inc. BIIB, +1.75% announced last week it was discontinuing Phase 3 trials of a potential blockbuster Alzheimer’s drug, Mizuho analyst Salim Syed declared, “Aducanumab is dead, and we’d argue so is the beta-amyloid hypothesis.”

Other analysts agreed. Biogen’s news, along with Roche’s discontinuation of two amyloid-based trials in January, “nearly close the door on the amyloid hypothesis,” SVB Leerink’s Marc Goodman wrote in a note on Thursday. Baird analyst Brian Skorney said in another note that the failure of aducanumab “should be the final nail in the coffin.”

Alzheimer’s researchers disagree.

The so-called amyloid hypothesis holds that the buildup of sticky protein fragments called beta amyloid plays a primary role in the progression of Alzheimer’s disease. And while none of the drugs targeting amyloid in Alzheimer’s patients has worked, that doesn’t mean that the hypothesis isn’t true.

The problem is when researchers are targeting beta amyloid, researchers say. By the time someone shows symptoms of Alzheimer’s — even very mild symptoms — it’s too late. Biogen’s aducanumab, a monoclonal antibody, targeted beta amyloid in patients with very early signs of Alzheimer’s disease.

“We know amyloid occurs at least a decade before symptoms appear,” said Rudy Tanzi, an Alzheimer’s researcher and vice chair of the neurology department at Massachusetts General Hospital in Boston. The build-up of amyloid leads to the formation of tau-containing neurofibrillary tangles, which kill a small number of brain cells. But the big problem is those tangles trigger neuroinflammation, killing neurons on a much larger scale.

Dr. Tanzi likens amyloid to a match that starts little brush fires of neurofibrillary tangles. Those brush fires spread and cause neuroinflammation, a forest fire that eventually destroys the brain.

“You don’t try to blow out the match after the fire is already blazing,” he said.

Read: Alzheimer’s and dementia are expected to grow, and could affect minority groups more

Also read: This is the one thing you must do if you’re caring for someone with Alzheimer’s

Biogen is still forging ahead on the amyloid hypothesis. On Friday, one day after the aducanumab announcement sent shares plummeting 29%, the company’s drug development partner Eisai Co., Ltd. ESALY, +0.36%  announced it was starting a Phase 3 trial of BAN2401, another drug that targets and promotes the clearance of beta amyloid in early-stage Alzheimer’s disease.

Dr. Tanzi was skeptical of the new trial, saying, “That’s too late, even for patients with mild symptoms. If you want to target amyloid, you have to do it in people who are still well.”

Roche Holding AG RHHBY, -0.47%  is doing just that with one of its trials of crenezumab, another monoclonal antibody designed to bind to and remove beta amyloid. The company pulled the plug earlier this year on two Phase 3 trials evaluating crenezumab’s effects on early Alzheimer’s symptoms, but the company is still evaluating the drug in a group of subjects in Colombia. These people, all healthy when enrolled, have a genetic mutation that leads to an early-onset form of Alzheimer’s disease. The idea here is that researchers are attacking amyloid earlier, before symptoms emerge and significant brain damage occurs.

See: One of the big reasons Alzheimer’s goes undiagnosed in older Americans

Also: Dementia doesn’t have to be the end — here’s how to live well

Dennis Selkoe, an Alzheimer’s researcher and neurologist at the Brigham and Women’s Hospital in Boston, thinks drugmakers should focus more on such prevention-type trials. He likened the approach to the use of statins in the prevention of cardiovascular disease. Patients who have certain cardiovascular risk factors take statins to lower their risk of a heart attack or stroke. Dr. Selkoe envisions something similar for Alzheimer’s: A drug that people who have a genetic predisposition or elevated levels of beta amyloid can take long before they begin to experience memory loss.

“The main reason targeting amyloid has failed isn’t because it’s biologically implausible, but because trials are targeting it too late in the disease,” Dr. Selkoe said. “The most advanced shots on goal are still amyloid approaches, whether investors like it or not.”

Some companies have ditched amyloid-based efforts, while others have left the Alzheimer’s space altogether. In June, AstraZeneca Plc AZN, +0.85%  and Eli Lilly & Co. LLY, +0.64%  announced they were scrapping late-stage trials of lanabecestat, a beta-site amyloid precursor protein cleaving enzyme (BACE) inhibitor designed to prevent the production of beta amyloid. Pfizer Inc. PFE, +0.43%  said in January 2018 that it was abandoning the development of Alzheimer’s and Parkinson’s drugs.

Don’t miss: From bats to bacteria: what scientists think might cause and stop Alzheimer’s

Several companies are branching out and moving beyond amyloid. Neurotrope Inc. NTRP, -3.34%  is studying a drug called Brystatin, which targets both amyloid and tau protein. What makes it different from other amyloid-busting drugs is that it also aims to restore the lost connections between brain cells, called synapses.

Alector Inc. ALEC, +3.67%  is looking at ways to possibly restore the brain’s immune system. The biotech is studying ways to target mutated genes that have been linked to neurodegeneration, with the goal of slowing or reversing the deterioration of the brain’s immune cells.

Denali Therapeutics Inc. DNLI, +7.55%  is zeroing in on ways to target brain inflammation, one of which is a drug that targets receptor-interacting protein kinase 1 (RIPK1), an enzyme that plays an important role in inflammation and cell death.

“We should be looking at other approaches,” said Brigham and Women’s Dr. Sekoe. “But the amyloid hypothesis is not dead.”

2 thoughts on “The Insider’s Guide to Alzheimer Drugs

  1. Hey, how’s it going?

    I want to pass along some very important news that everyone needs to hear!

    In December of 2017, Donald Trump made history by recognizing Jerusalem as the captial of Israel. Why is this big news? Because by this the Jewish people of Israel are now able to press forward in bringing about the Third Temple prophesied in the Bible.

    The Jewish people deny Jesus as their Messiah and have stated that their Messiah has been identified and is waiting to be revealed. They say this man will rule the world under a one world religion called “spiritualism”.

    They even printed a coin to raise money for the Temple with Donald Trumps face on the front and with king Cyrus'(who built the second Temple) behind him. On the back of the coin is an image of the third Temple.

    The Bible says this false Messiah who seats himself in the Third Temple will be thee antichrist that will bring about the Great Tribulation, though the Jewish people believe he will bring about world peace. It will be a false peace for a period of time. You can watch interviews of Jewish Rabbi’s in Israel speaking of these things. They have their plans set in place. It is only years away!

    More importantly, the power that runs the world wants to put a RFID microchip in our body making us total slaves to them. This chip matches perfectly with the Mark of the Beast in the Bible, more specifically Revelation 13:16-18:

    He causes all, both small and great, rich and poor, free and slave, to receive a mark on their right hand or on their foreheads, and that no one may buy or sell except one who has the mark or the name of the beast, or the number of his name.

    Here is wisdom. Let him who has understanding calculate the number of the beast, for it is the number of a man: His number is 666.

    Referring to the last days, this could only be speaking of a cashless society, which we have yet to see, but are heading towards. Otherwise, we could still buy or sell without the mark amongst others if physical money was still currency. RFID microchip implant technology will be the future of a one world cashless society containing digital currency. It will be implanted in the right-hand or the forehead, and we cannot buy or sell without it! We must grow strong in Jesus. AT ALL COSTS, DO NOT TAKE IT!

    Then a third angel followed them, saying with a loud voice, “If anyone worships the beast and his image, and receives his mark on his forehead or on his hand, he himself shall also drink of the wine of the wrath of God, which is poured out full strength into the cup of His indignation. He shall be tormented with fire and brimstone in the presence of the holy angels and in the presence of the Lamb. And the smoke of their torment ascends forever and ever; and they have no rest day or night, who worship the beast and his image, and whoever receives the mark of his name.” (Revelation 14:9-11).

    People have been saying the end is coming for many years, but we need two key things. One, the Third Temple, and two, the technology for a cashless society to fulfill the prophecy of the Mark of the Beast.


  2. Hello. Very interesting article but it’s hard to find in search results.

    You are out of google’s top ten, so you can’t
    expect big traffic. You need hi quality backlinks to rank in serps.

    And you can get them for free, just search in google: fasrixo’s tools

Leave a Reply

Your email address will not be published. Required fields are marked *

Egg Whites International